About this trial
The purpose of the study is to investigate the cardiovascular disease (CVD) risk profile among participants newly diagnosed with type 2 diabetes mellitus (T2DM) in Southeast Asia (CRISTAL SEA). It's a retrospective chart-review across five Southeast Asian countries to characterize newly diagnosed T2DM participants and how their CVD risk is distributed, using data from the year before diagnosis and roughly the first year after diagnosis.
Eligibility criteria
Qualifiers
Aged greater than equal to (≥) 40 and less than (<) 70 years
Male or female
Newly diagnosed with T2DM and initiated on anti-hyperglycemic treatment between 1 January 2022 and 31 December 2023
Disqualifiers
If any exclusion criterion is met, the participant will be excluded from the study.
T1DM or gestational diabetes
Prescribed with any anti-hyperglycemic medications before first diagnosis of T2DM
Pregnant women
Trial design
Treatments tested in this trial
- No treatment given